Monday, January 04, 2021 5:47:17 PM
(b) Effect on Capital Stock.
Conversion of Coeptis Shares. At the Closing, each Coeptis Share issued and outstanding on the Closing Date (as defined in Section 3, below) shall, by virtue of the Merger and without any further action on the part of Coeptis, Vinings, Acquisition Sub, or the holders of the Coeptis Shares as of the Closing Date (the “Original Holders”), be converted into and exchanged for one share of validly issued, fully paid and non-assessable common stock of Vinings (the “Share Ratio”) such that the Original Holders will be issued a total of twenty-five million one hundred and seventy-eight thousand eight hundred and forty (25,178,840) shares of common stock of Vinings (the “Vinings Common Stock”) as a result of the merger, and such shares shall be distributed pro rata to the holders of one hundred percent (100%) of the Coeptis common stock, subject to the receipt of letters of transmittal and any other documents required of the transfer agent; provided that the number of shares of Vinings Common Stock to be issued in connection with the Merger shall be increased on a one-for-one basis for each share of Coeptis Common Stock issued by Coeptis between the Effective Date and the Closing Date (which number of additional shares shall not exceed five million (5,000,000) without Vinings’ consent). All shares of Vinings Common Stock issued upon the exchange of Coeptis Shares in accordance with the terms hereof shall (i) contain a standard restricted securities legend in compliance with the Securities Act and (ii) be deemed to have been issued in full satisfaction of all rights pertaining to such Coeptis Shares. There shall be no further registration of transfers on the stock transfer books of Coeptis of the Coeptis Shares that were outstanding immediately prior to the Closing.
Recent COEP News
- Coeptis Therapeutics to Present its Universal Allogeneic SNAP-CAR NK Cell Therapy at the ISCT 2024 • PR Newswire (US) • 05/08/2024 12:47:00 PM
- Coeptis Therapeutics Announces Poster Data Presentation at American Society of Gene & Cell Therapy (ASGCT) 27th Annual Meeting • PR Newswire (US) • 05/02/2024 12:47:00 PM
- Coeptis Therapeutics Congratulates Alexander Deiters, Professor at the University of Pittsburgh, on Receiving the 2024 Chancellor's Distinguished Research Award • PR Newswire (US) • 04/02/2024 12:47:00 PM
- Coeptis Therapeutics Adds Autoimmune Indications to Exclusive License Agreement with University of Pittsburgh for SNAP-CAR T and SNAP-CAR NK • PR Newswire (US) • 02/26/2024 02:00:00 PM
- Coeptis Therapeutics to Pursue Phase 2 Program Using Proprietary First-in-Class Allogeneic NK Cell Therapy for the Treatment of Viral Infections • PR Newswire (US) • 02/07/2024 12:30:00 PM
- Coeptis Therapeutics President and CEO Issues Letter to Shareholders Highlighting 2023 Accomplishments and Outlook for 2024 • PR Newswire (US) • 01/04/2024 12:30:00 PM
- Coeptis Therapeutics Announces Research Demonstrating the Potential of SNAP-CAR T-cells to Reduce Tumor Burden and Growth in HER2 and CD20 Expressing Cancers Will be Presented at SITC 2023 • PR Newswire (US) • 10/31/2023 01:01:00 PM
- Coeptis Therapeutics Announces $2 Million Private Placement • PR Newswire (US) • 10/24/2023 12:30:00 PM
- Coeptis Therapeutics Expands License Agreement with University of Pittsburgh to Include SNAP-CAR NK Cell Technology • PR Newswire (US) • 10/11/2023 11:30:00 AM
- Coeptis Therapeutics to Participate in Panel at the BioFlorida Conference Discussing Emerging Cell and Gene Therapies • PR Newswire (US) • 10/09/2023 01:15:00 PM
- Coeptis Therapeutics Announces Research Involving SNAP-CAR Accepted for Presentation at the Society for Immunotherapy of Cancer's 38th Annual Meeting • PR Newswire (US) • 10/04/2023 11:30:00 AM
- Coeptis Therapeutics to Present at the 2023 Cell & Gene Meeting on the Mesa • PR Newswire (US) • 09/27/2023 11:30:00 AM
- Coeptis Therapeutics Provides Safety and Dosing Update from Phase 1 Trials Investigating DVX201 in Relapsed/Refractory AML or High Risk MDS and Hospitalized COVID-19 Infection • PR Newswire (US) • 09/14/2023 11:30:00 AM
- Coeptis Therapeutics Announces Deverra Therapeutics Has Received Two Life Science Start-Up and Development Awards and Associated Grant from Washington's Cancer Research Endowment • PR Newswire (US) • 09/11/2023 11:30:00 AM
- Coeptis Therapeutics Appoints Colleen Delaney, MD, as Chief Scientific and Medical Officer • PR Newswire (US) • 08/30/2023 05:00:00 PM
- Coeptis Therapeutics Completes Exclusive License for Allogeneic Immuno-Oncology Platform and Clinical Stage Assets from Deverra Therapeutics • PR Newswire (US) • 08/17/2023 11:30:00 AM
- Coeptis Therapeutics Files FDA 513(g) Submission for CD38 In Vitro Companion Diagnostic • PR Newswire (US) • 08/01/2023 12:00:00 PM
- Coeptis Therapeutics Holdings, Inc. Announces Closing of $3.5 Million Underwritten Offering • PR Newswire (US) • 06/16/2023 08:00:00 PM
- Coeptis Therapeutics Holdings, Inc. Announces Pricing of $3.5 Million Underwritten Offering • PR Newswire (US) • 06/14/2023 01:28:00 PM
- Coeptis Therapeutics Receives Approval to Transfer to The Nasdaq Capital Market • PR Newswire (US) • 06/09/2023 11:00:00 AM
- Coeptis Therapeutics Appoints Brian Cogley as Chief Financial Officer • PR Newswire (US) • 05/17/2023 12:30:00 PM
Avant Technologies Equipping AI-Managed Data Center with High Performance Computing Systems • AVAI • May 10, 2024 8:00 AM
VAYK Discloses Strategic Conversation on Potential Acquisition of $4 Million Home Service Business • VAYK • May 9, 2024 9:00 AM
Bantec's Howco Awarded $4.19 Million Dollar U.S. Department of Defense Contract • BANT • May 8, 2024 10:00 AM
Element79 Gold Corp Successfully Closes Maverick Springs Option Agreement • ELEM • May 8, 2024 9:05 AM
Kona Gold Beverages, Inc. Achieves April Revenues Exceeding $586,000 • KGKG • May 8, 2024 8:30 AM
Epazz plans to spin off Galaxy Batteries Inc. • EPAZ • May 8, 2024 7:05 AM